Cubist Systematic Strategies LLC Purchases 24,870 Shares of Mesoblast Limited (NASDAQ:MESO)

Cubist Systematic Strategies LLC increased its position in Mesoblast Limited (NASDAQ:MESO) by 241.0% during the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 35,191 shares of the company’s stock after purchasing an additional 24,870 shares during the period. Cubist Systematic Strategies LLC’s holdings in Mesoblast were worth $697,000 at the end of the most recent quarter.

Several other large investors have also bought and sold shares of MESO. Lindbrook Capital LLC raised its stake in shares of Mesoblast by 70.9% during the 4th quarter. Lindbrook Capital LLC now owns 2,172 shares of the company’s stock worth $43,000 after purchasing an additional 901 shares during the period. R Squared Ltd bought a new stake in Mesoblast in the 4th quarter valued at about $30,000. Prosperity Wealth Management Inc. grew its holdings in Mesoblast by 2.0% during the 4th quarter. Prosperity Wealth Management Inc. now owns 93,245 shares of the company’s stock valued at $1,846,000 after buying an additional 1,795 shares in the last quarter. Quadrant Capital Group LLC grew its holdings in Mesoblast by 41.1% during the 4th quarter. Quadrant Capital Group LLC now owns 6,496 shares of the company’s stock valued at $129,000 after buying an additional 1,891 shares in the last quarter. Finally, Barclays PLC purchased a new position in Mesoblast during the 4th quarter valued at about $38,000. 1.43% of the stock is currently owned by institutional investors.

Mesoblast Stock Performance

Shares of MESO stock opened at $11.95 on Friday. The company has a current ratio of 1.18, a quick ratio of 1.18 and a debt-to-equity ratio of 0.21. The stock has a 50 day moving average price of $11.81 and a two-hundred day moving average price of $13.79. Mesoblast Limited has a fifty-two week low of $5.78 and a fifty-two week high of $22.00.

Wall Street Analysts Forecast Growth

Several research analysts have recently commented on MESO shares. Cantor Fitzgerald raised Mesoblast to a “strong-buy” rating in a report on Monday, March 31st. Piper Sandler reissued an “overweight” rating and set a $24.00 price target (up from $15.00) on shares of Mesoblast in a research note on Friday, February 7th. One analyst has rated the stock with a sell rating, one has given a hold rating, two have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $18.00.

Mesoblast Company Profile

Mesoblast Limited engages in the development of regenerative medicine products in Australia, the United States, Singapore, and Switzerland. The company offers products in the areas of cardiovascular, spine orthopedic disorder, oncology, hematology, and immune-mediated and inflammatory diseases. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells.